Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.76 |
| ▸ | ITGAV | P06756 | 16/20 | 0.76 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.76 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.32 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382269 | 0.95 | ITGB3 (0.75) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL382633 | 0.94 | ITGB3 (0.68) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL382754 | 0.94 | ITGB3 (0.75) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL382444 | 0.93 | ITGB3 (0.75) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL381993 | 0.92 | ITGB3 (0.65) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL382271 | 0.92 | ITGB3 (0.65) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL382861 | 0.90 | ITGB3 (0.68) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6499246 | 0.89 | ITGB3 (0.67) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL383817 | 0.89 | ITGB3 (0.61) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL381996 | 0.88 | ITGB3 (0.75) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420558-B1 | COMPOUNDS WITH AMIDINE GROUPS ANTAGONISTIC ACTIVITY, CELL ADHESION INHIBITORY ACTIVITY, HUMAN PLATELET AGGREGATION INHIBITORY ACTIVITY, AND THERAPEUTIC AGENTS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-16 | — | — | US | claimed |
| EP-1074543-A1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2001-02-07 | — | — | EP | claimed |
| EP-1074543-B1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA PHARMA CO LTD (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1250935-A1 | REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
| US-6420558-B1 | COMPOUNDS WITH AMIDINE GROUPS ANTAGONISTIC ACTIVITY, CELL ADHESION INHIBITORY ACTIVITY, HUMAN PLATELET AGGREGATION INHIBITORY ACTIVITY, AND THERAPEUTIC AGENTS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1074543-A1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGAV 2/4885ITGA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.